Immunocore stock reports 16 percent first half revenue growth

Published on 10/07/2026 at 07:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Immunocore stock was last at USD 29.59 on October 5, 2026, as first-half KIMMTRAK sales reached USD 223 million. Q2 sales grew 18 percent year over year.

IMCR, US45258D1054, Illustration mit AI erstellt.

Immunocore stock (ISIN US45258D1054) was last at USD 29.59 on Nasdaq on October 5, 2026, down 0.40 percent from the prior close. The latest operating picture is stronger than the daily move: first-half 2026 KIMMTRAK sales reached USD 223 million, up 16 percent year over year, according to Benzinga.

KIMMTRAK sales reach USD 223 million

The company generated USD 116 million in second-quarter sales, an 18 percent increase from Q2 2025. The United States contributed USD 75 million, up 17 percent year over year, while Europe generated USD 34 million, according to Benzinga.

The comparison carries an important qualification. Management said USD 6 million of US distributor inventory stocking supported the quarter, leaving underlying sequential growth at 3 percent and pointing to a more measured commercial trajectory as penetration rises.

Loss narrows as trials advance

Immunocore reported a quarterly net loss of under USD 1 million, compared with a USD 10 million loss in the same period of 2025. Cash and marketable securities stood at USD 880 million on June 30, 2026, giving the company room to fund its pipeline while research spending continues.

The principal clinical checkpoint is TEBE-AM, a Phase 3 trial testing KIMMTRAK in previously treated advanced melanoma. StockTitan reports that target enrollment reached 540 patients on September 14, 2026, with topline overall-survival data expected as early as the end of 2026.

Consensus target stays above USD 29.59

According to Paasa, the consensus rating is Buy, based on 14 buy ratings and 5 holds. The median target is USD 39.00, with a low of USD 35.00 and a high of USD 43.00, putting the median 31.8 percent above the October 5 price.

For investors, the tension is visible in the numbers: commercial revenue is growing, but management expects moderation after five years of KIMMTRAK commercialization. The next valuation test is therefore tied to execution in the melanoma pipeline, not only to the latest quarterly sales increase.

Immunocore stock was last at USD 29.59

Immunocore stock was last at USD 29.59 on Nasdaq on October 5, 2026, with a daily change of minus 0.40 percent. Market capitalization was USD 1.5 billion as of October 6, 2026.